Please upgrade your browser.
The purpose of this analysis from the phase II trial was to investigate the effects of tasquinimod on selected biomarkers to confirm preclinical findings on the mechanism of action.
Rarely, renal cell carcinomas may also contain evidence of macroscopic fat.
Matt Cardle on why he fights for thousands of children struck by a rare and deadly disease
Researchers at the University of California, San Diego School of Medicine have found that recovery from an emerging, minimally invasive surgical technique called Laparo-Endoscopic Single-Site Surgery (LESS) was less painful for kidney cancer patients than traditional laparoscopic surgery.
The FDA said today it has approved regorafenib (Stivarga) as a new treatment in the U.S. for patients with colorectal cancer that has spread after treatment with prior therapies.
This annual meeting attracts an audience of hundreds of medical practitioners and scientists from the US, Asia, Europe, and Latin America.
A comprehensive analysis of prognostic factors.
The Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this research grant is to fund physicians during the transition from a fellowship program to a faculty appointment.
The majority of the responses seen with BMS-936558 lasted longer than one year. In addition, these anti-PD-1 antibodies managed to shrink away large metastatic tumors like lung and kidney, which are typically pretty resistant to therapy.
POC Clinical Program of a New Anti-Tumor Drug Candidate MBC-11 Targeting Metastatic Bone Disease Read more: Maxwell Biotech Venture Fund Invests in POC Clinical Program of a New Anti-Tumor Drug Candi
In early September the investment committee of Maxwell Biotech Venture Fund (âMBVFâ), founded with the participation of the Russian Governmentâs RVC, approved the binding terms and the amount of an investment in a newly established private Russian biotech company, Osteros Biomedica, Ltd, formed for the development and commercialization of drugs for the treatment of cancer-induced bone disease.
|NeonCRM by Neon One|